Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography

• Published in: Blood coagulation & fibrinolysis Vol. 29; no. 6; pp. 521 - 527
• Main Authors: Gantioqui, Jorell, Stevic, Ivan, Atkinson, Helen, Chan, Anthony K.C
• Format: Journal Article
• Language: English
• Published: England Copyright YEAR Wolters Kluwer Health, Inc. All rights reserved 01-09-2018
• Subjects: Anticoagulants - pharmacology; Blood Coagulation - drug effects; Blood Coagulation Tests; Blood Platelets - drug effects; Dabigatran - pharmacology; Heparin - pharmacology; Humans; Rivaroxaban - pharmacology; Thrombelastography - methods
• ISSN: 0957-5235; 1473-5733
• DOI: 10.1097/MBC.0000000000000751

OBJECTIVECurrent recommendations for treating patients with thromboembolism and concomitant thrombocytopenia are based on anecdotal data and expert opinion, rather than clinical studies. Our aim was to use an in-vitro model employing thromboelastography (TEG) to evaluate clot formation as a surrogate indicator of clinical tendency to hemorrhage, and investigate the interactions of plasma at varying concentrations of platelets in the presence of anticoagulants.
METHODSPlatelet-rich and platelet-poor plasma isolated from whole blood were mixed together to obtain platelet concentrations ranging from less than 10–150 × 10 platelets/l. Clotting was initiated with tissue factor and measured by TEG.
RESULTSDifferent tissue factor concentrations were required to model clinical clotting profiles for plasma that contained heparin (UFH), low molecular weight heparin (LMWH), or fondaparinux. No tissue factor was required for rivaroxaban or dabigatran-clotting reactions. The time to initiate coagulation (R) was significantly delayed at platelet concentrations less than 30 × 10/l for UFH and LMWH, less than 20 × 10/l for fondaparinux, and less than 10 × 10/l for rivaroxaban and dabigatran. The strength of the clot was significantly compromised at all platelet concentrations in the presence of UFH, LMWH or fondaparinux. In contrast, rivaroxaban and dabigatran compromised clot strength at platelet concentrations less than 10 × 10/l.
CONCLUSIONAll anticoagulants tested compromised coagulation at specific platelet concentration thresholds. Rivaroxaban and dabigatran had reduced impact on clot formation at low-platelet concentrations compared with heparinoids, suggesting that the factor-specific inhibitors may be more favorable than traditional heparin-based treatment of thromboembolism in the presence of thrombocytopenia.